Richards Group Inc. Announces 2026 Second Quarter Results: Revenue Growth of 5% Primarily on Acquisitions; Gross Margins up 18%

Rhea-AI Summary

Richards Group (TSX: RIC, OTC: RPKIF) reported 2026 second quarter results for the period ended June 30, 2026. Total revenue increased 5.2%, primarily from acquisitions including DermapenWorld (June 2025) and PharmaSystems (May 2026). Organic Healthcare revenue rose 7.3%, driven by consumables and low-price capital equipment across the Aesthetic and Pharmacy verticals.

Packaging revenue declined 11.5%, an improvement versus the 17.2% decline in the first quarter and still reflecting macroeconomic conditions. Gross margins increased 18.4%, supported by the recent acquisitions. The company also completed its normal course issuer bid, repurchasing 450,926 shares. Management highlighted progress toward its 2030 Vision, citing continued Healthcare growth, improving margins through customer and product mix, and what it described as an inflection point in earnings and cash flow generation. Full results and a podcast are available on the company’s website and on SEDAR+.

Positive

• Total revenue up 5.2% in Q2 2026, driven by acquisitions
• Organic Healthcare revenue increased 7.3%, led by Aesthetic and Pharmacy
• Gross margins grew 18.4% in the quarter on recent acquisitions
• NCIB completed with 450,926 shares repurchased

Negative

• Packaging revenue declined 11.5% year-over-year in Q2 2026

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today results for the quarter ended June 30, 2026.

Second Quarter 2026 Highlights:

• Revenue contributions from acquisitions including DermapenWorld (June 2025) and PharmaSystems (May 2026) drove overall increase of 5.2%.

• Organic Healthcare revenue up 7.3%, representing a solid quarter with strong performance in each of our core Aesthetic and Pharmacy verticals. Growth was driven by consumables and low-price capital equipment.

• Packaging revenue fell 11.5%, lower than the 17.2% experienced in the first quarter and continuing to reflect the macro environment.

• Gross margins in the quarter grew 18.4% on above-mentioned acquisitions.

• Completed NCIB through the purchase of 450,926 shares

Management Comments:

"Our 2030 Vision is bearing fruit with continued growth in healthcare and improving gross margins via customer and product mix, crossing an inflection point in earnings and cash flow generation" commented John Glynn, President and Chief Executive Officer.

Details of the Company's results and podcast are currently available on the Company's website at www.richardsgroup.com and on SEDAR+ at www.sedarplus.ca.

FOR MORE INFORMATION CONTACT:

John Glynn Director and Chief Executive Officer Richards Group Inc. jglynn@richardsgroup.com

Enzio Di Gennaro Chief Financial Officer Richards Group Inc. edigennaro@richardsgroup.com

 

Please visit our YouTube channel at https://www.youtube.com/@RichardsGroup_RIC

About Richards Group Inc.
Founded in 1912 and headquartered in Mississauga, Ontario, Canada, Richards Group operates across two core segments, Healthcare and Packaging, serving a global customer base with market leading medical devices, supplies, and equipment, as well as a diverse offering of glass and plastic packaging solutions. Richards is the largest Canadian distributor in aesthetic, pharmacy, and vision care devices, the third largest in Canadian packaging, and is newly developing a medical device global OEM footprint. The company differentiates itself through product innovation, high touch service, and deep industry expertise. For more information, visit richardsgroup.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/307359

FAQ

How did Richards Group (RPKIF) perform in its 2026 second quarter results?

Richards Group reported a 5.2% revenue increase in Q2 2026. According to Richards Group, growth was mainly driven by acquisitions, while organic Healthcare revenue rose 7.3% and Packaging revenue declined 11.5%, reflecting ongoing macroeconomic pressures on that segment.

What drove revenue growth for Richards Group (RPKIF) in Q2 2026?

Revenue growth of 5.2% in Q2 2026 was primarily driven by acquisitions. According to Richards Group, DermapenWorld and PharmaSystems contributed to the increase, while organic Healthcare revenue also grew 7.3% on stronger consumables and low-price capital equipment sales.

How did gross margins change for Richards Group (RPKIF) in Q2 2026?

Gross margins increased by 18.4% in Q2 2026. According to Richards Group, this improvement was linked to contributions from the DermapenWorld and PharmaSystems acquisitions and an enhanced customer and product mix within its Healthcare-focused businesses.

What happened to Richards Group’s Packaging revenue in Q2 2026?

Packaging revenue fell 11.5% in Q2 2026. According to Richards Group, this decline was smaller than the 17.2% drop in the first quarter and continued to reflect broader macroeconomic conditions affecting the Packaging segment’s demand.

Did Richards Group (RPKIF) complete a share buyback in the 2026 second quarter?

Yes, Richards Group completed its normal course issuer bid in Q2 2026. According to Richards Group, the company repurchased 450,926 shares, reducing shares outstanding and potentially enhancing per-share metrics for remaining shareholders over time.

What is Richards Group’s 2030 Vision and how did it impact Q2 2026 results?

Management linked Q2 2026 progress to its 2030 Vision strategy. According to Richards Group, continued Healthcare growth, improved gross margins from customer and product mix, and an inflection point in earnings and cash flow support this long-term vision.